Roche Holding AG (RHHVF)

OTCMKTS · Delayed Price · Currency is USD
327.04
-3.48 (-1.05%)
Jul 28, 2025, 2:26 PM EDT
-1.05%
Market Cap279.51B
Revenue (ttm)79.83B
Net Income (ttm)11.86B
Shares Outn/a
EPS (ttm)n/a
PE Ratio23.58
Forward PE13.81
Dividend10.98 (3.32%)
Ex-Dividend DateMar 27, 2025
Volume9
Average Volume4,420
Open329.19
Previous Close330.52
Day's Range323.77 - 329.19
52-Week Range269.80 - 354.19
Beta0.17
RSI55.18
Earnings DateJul 24, 2025

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]

Sector Healthcare
Founded 1896
Employees 103,249
Stock Exchange OTCMKTS
Ticker Symbol RHHVF
Full Company Profile

Financial Performance

In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.

Financial numbers in CHF Financial Statements

News

Roche presents new insights in Alzheimer's disease research across its diagnostics and pharmaceutical portfolios at AAIC

Basel, 28 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being presented at the Alzheimer's Association International Confer...

19 hours ago - GlobeNewsWire

Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being pres...

19 hours ago - Business Wire

Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports

Swiss drugmaker Roche Holding plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday.

1 day ago - Reuters

Roche Holding AG 2025 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Roche Holding AG in conjunction with their 2025 Q2 earnings call.

3 days ago - Seeking Alpha

Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy

On Friday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional marketing authorisation (CMA) for Elevidys (del...

3 days ago - Benzinga

Roche Diagnostics showcases science-driven leadership and innovation at ADLM 2025

Lead With Us -- a promise for innovative partnerships, better insights, faster support, and improved healthcare outcomes. INDIANAPOLIS and CHICAGO , July 24, 2025 /PRNewswire/ -- Roche (SIX: RO, ROG; ...

4 days ago - PRNewsWire

Significant amount of U.S. investment pledged, says Roche CEO

Thomas Schinecker, CEO of Roche, discusses the company's earnings and what the pharmaceutical industry in Europe is doing to win favour with the Trump administration.

4 days ago - CNBC

Roche considering selling drugs directly to US patients, CEO says

Roche is considering selling its prescription medicines in the U.S. directly to consumers to lower costs for patients as part of talks with the U.S. government, which is pressuring drugmakers to cut p...

4 days ago - Reuters

Roche confirms guidance as H1 core operating profit up 6%

Swiss drugmaker Roche reported first-half operating profit up 6% on Thursday at a forecast-beating 12 billion Swiss francs ($15.15 billion) and also confirmed its full-year outlook.

4 days ago - Reuters

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025

Basel, 24 July 2025 Group sales grew by 7%1 at constant exchange rates (CER; 4% in CHF), driven by strong demand for medicines. Pharmaceuticals Division sales rose by 10% (6% in CHF), with Phesgo (bre...

4 days ago - GlobeNewsWire

The Roche Associates, Inc. Named “Top Senior Living Marketing Agency 2025”

East Longmeadow, MA, July 23, 2025 (GLOBE NEWSWIRE) -- The Roche Associates, Inc. was recently named “Top Senior Living Marketing Agency for 2025” by Elder Care Review. The Roche Associates, Inc. emer...

5 days ago - GlobeNewsWire

Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer's disease

Basel, 23 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it has received CE Mark for its Elecsys® pTau181 test to measure phosphorylated Tau (pTau) 181 protein which is an indicator of...

5 days ago - GlobeNewsWire

European Commission approves Roche's Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation

Basel, 23 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Itovebi™ (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, fo...

5 days ago - GlobeNewsWire

Roche pauses shipments of Elevidys gene therapy outside the US, Bloomberg News reports

Roche Holding AG paused all shipments of the controversial gene therapy Elevidys, Bloomberg News reported on Tuesday.

6 days ago - Reuters

Roche's Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)

Basel, 22 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its Board of Directors' decision to propose to shareholders a modernisation of Roche Holding Ltd's capital structure for approv...

6 days ago - GlobeNewsWire

Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today topline results from the pivotal Phase IIb ALIENTO (n=1,301) and the ...

7 days ago - Business Wire

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease

Basel, 21 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) trials investigating astegolima...

7 days ago - GlobeNewsWire

Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Re...

10 days ago - Business Wire